PIK3CA mutation – Medxy AI

Targeting the PI3K/AKT Pathway: Ipatasertib Shows Promise as Maintenance Therapy for PIK3CA-Mutated, HER2-Positive Metastatic Breast Cancer

By MedXY 01/13/2026

The Phase 1b SOLTI-1507 IPATHER trial demonstrates that adding the AKT inhibitor ipatasertib to trastuzumab and pertuzumab is a safe and clinically active maintenance strategy for patients with PIK3CA-mutated HER2-positive metastatic breast cancer, potentially overcoming therapeutic resistance.

Clinical Updates Oncology

Adjuvant Aspirin in PIK3CA-Mutated Colon Cancer: Insights from the SAKK 41/13 Randomized Trial

By MedXY 09/19/2025

The SAKK 41/13 trial provides the first prospective randomized evidence that adjuvant aspirin may improve disease-free survival in patients with resected PIK3CA-mutated stage II and III colon cancer, suggesting its potential as a safe, cost-effective adjuvant strategy.

Clinical Updates news Oncology Specialties

Low-Dose Aspirin’s Impact on PI3K-Altered Localized Colorectal Cancer: New Evidence from a Randomized Controlled Trial

By MedXY 09/19/2025

This randomized trial confirms that daily low-dose aspirin significantly reduces colorectal cancer recurrence in patients with PI3K pathway mutations, highlighting a targeted adjunctive therapy option.

Clinical Updates news Oncology Specialties

Inavolisib Improves Overall Survival in PIK3CA-Mutated Advanced Breast Cancer: Results from the INAVO120 Study

By MedXY 08/01/2025

Inavolisib combined with palbociclib and fulvestrant significantly prolongs overall survival in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, but increases certain toxicities.